{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:44:41Z","timestamp":1793371481538,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.yebeh.2021.108358","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T08:46:05Z","timestamp":1635324365000},"page":"108358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy"],"prefix":"10.1016","volume":"125","author":[{"given":"Rajpushpa","family":"Labh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3377-9626","authenticated-orcid":false,"given":"Rachna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108358_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2017.11.015","article-title":"The new definition and classification of seizures and epilepsy","volume":"139","author":"Falco-Walter","year":"2018","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2021.108358_b0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pediatrneurol.2016.01.004","article-title":"Pediatric sudden unexpected death in epilepsy","volume":"57","author":"Morse","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1092852900008452","article-title":"The goal of epilepsy therapy: no seizures, no side effects, as soon as possible","volume":"9","author":"Engel","year":"2004","journal-title":"CNS Spectr"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/CON.0000000000000712","article-title":"Antiepileptic drug treatment of epilepsy in children","volume":"25","author":"Moosa","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108358_b0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41582-020-00419-y","article-title":"Drug-resistant epilepsy - Time to target mechanisms","volume":"16","author":"Lerche","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108358_b0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12098-014-1533-1","article-title":"Refractory epilepsy in children","volume":"81","author":"Aneja","year":"2014","journal-title":"Indian J Pediatr"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy","volume":"1863","author":"Clossen","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1586\/ern.13.54","article-title":"Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation","volume":"13","author":"D\u2019Ambrosio","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"1 suppl.","key":"10.1016\/j.yebeh.2021.108358_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5698\/1535-7511-14.s2.3","article-title":"Epilepsy and inflammation in the brain: overview and pathophysiology","volume":"14","author":"Vezzani","year":"2014","journal-title":"Epilepsy Curr"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108358_b0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2021.108358_b0060","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ejps.2017.05.035","article-title":"Biomarkers in epilepsy\u2013A modelling perspective","volume":"109","author":"van Dijkman","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"37","key":"10.1016\/j.yebeh.2021.108358_b0065","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.2174\/1381612823666170926113754","article-title":"Inflammation and epilepsy: preclinical findings and potential clinical translation","volume":"23","author":"Terrone","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/nan.12444","article-title":"Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies","volume":"44","author":"van Vliet","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/neu.2016.47","article-title":"Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms","volume":"29","author":"Alyu","year":"2017","journal-title":"Acta Neuropsychiatr"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12974-018-1192-7","article-title":"The role of inflammation in the development of epilepsy","volume":"15","author":"Rana","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108358_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114096","article-title":"Reactive glia inflammatory signaling pathways and epilepsy","volume":"21","author":"Sanz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"43","key":"10.1016\/j.yebeh.2021.108358_b0090","doi-asserted-by":"crossref","first-page":"11083","DOI":"10.1523\/JNEUROSCI.2766-06.2006","article-title":"Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy","volume":"26","author":"Gorter","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2021.108358_b0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jocn.2015.07.033","article-title":"Higher expression of monocyte chemoattractant protein 1 and its receptor in brain tissue of intractable epilepsy patients","volume":"28","author":"Wang","year":"2016","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/dna.2016.3345","article-title":"Epilepsy, seizures, and inflammation: role of the C-C motif ligand 2 chemokine","volume":"35","author":"Bozzi","year":"2016","journal-title":"DNA Cell Biol"},{"issue":"13","key":"10.1016\/j.yebeh.2021.108358_b0105","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1523\/JNEUROSCI.0451-15.2016","article-title":"The chemokine CCL2 mediates the seizure-enhancing effects of systemic inflammation","volume":"36","author":"Cerri","year":"2016","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-6-40","article-title":"Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus","volume":"6","author":"Foresti","year":"2009","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-10-11","article-title":"Monocyte chemoattractant protein-1 affects migration of hippocampal neural progenitors following status epilepticus in rats","volume":"10","author":"Hung","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-019-0509-5","article-title":"Evaluation of IL-1\u03b2 levels in epilepsy and traumatic brain injury in dogs","volume":"20","author":"Kostic","year":"2019","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000243081","article-title":"Levels of IL-1\u03b2 and IL-1RA in cerebrospinal fluid of human patients after single and prolonged seizures","volume":"17","author":"Lehtim\u00e4ki","year":"2010","journal-title":"NeuroImmunoModulation"},{"issue":"33","key":"10.1016\/j.yebeh.2021.108358_b0130","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1523\/JNEUROSCI.0982-17.2017","article-title":"Interleukin-1 receptor in seizure susceptibility after traumatic injury to the pediatric brain","volume":"37","author":"Semple","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2021.108358_b0135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fncel.2014.00155","article-title":"The inflammatory molecules IL-1\u03b2 and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy","volume":"8","author":"Chiavegato","year":"2014","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/GIM.0b013e318161317c","article-title":"Association study between interleukin 1\u03b2 gene and epileptic disorders: a HuGe review and meta-analysis","volume":"10","author":"Kauffman","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.yebeh.2021.108358_b0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2018.02.041","article-title":"Levetiracetam mitigates lipopolysaccharide-induced JAK2\/STAT3 and TLR4\/MAPK signaling pathways activation in a rat model of adjuvant- induced arthritis","volume":"826","author":"Abed El-Gaphar","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/epi.12473","article-title":"Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia\/microglia co-culture model of inflammation","volume":"55","author":"Dambach","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108358_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/806162","article-title":"Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-CD40-stimulated blood in vitro","volume":"2014","author":"Himmerich","year":"2014","journal-title":"Oxid Med Cell Longev"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108358_b0160","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.jpsychires.2013.07.026","article-title":"Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro","volume":"47","author":"Himmerich","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108358_b0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5698\/1535-7597-13.4.158","article-title":"Stress and seizure control in children: Where to now?","volume":"13","author":"Caplan","year":"2013","journal-title":"Epilepsy Curr"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108358_b0170","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.seizure.2011.06.004","article-title":"Depression and anxiety in childhood epilepsy: a review","volume":"20","author":"Reilly","year":"2011","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s10862-017-9637-3","article-title":"Development of the Spence children\u2019s anxiety scale - Short version (SCAS-S)","volume":"40","author":"Ahlen","year":"2018","journal-title":"J Psychopathol Behav Assess"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108358_b0180","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0005-7967(98)00034-5","article-title":"A measure of anxiety symptoms among children","volume":"36","author":"Spence","year":"1998","journal-title":"Behav Res Ther"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0185","doi-asserted-by":"crossref","first-page":"e1532","DOI":"10.1542\/peds.2011-0245","article-title":"Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy","volume":"128","author":"Baca","year":"2011","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108358_b0190","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejpn.2014.12.022","article-title":"Factors associated with quality of life in active childhood epilepsy: a population-based study","volume":"19","author":"Reilly","year":"2015","journal-title":"Eur J Paediatric Neurol"},{"key":"10.1016\/j.yebeh.2021.108358_b0195","series-title":"Epilepsy and the Interictal State","first-page":"15","article-title":"Epilepsy, comorbidities, and consequences: implications for understanding and combating stigma","author":"St Louis","year":"2015"},{"key":"10.1016\/j.yebeh.2021.108358_b0200","series-title":"Epileptology - The modern state of science","article-title":"Psychiatric comorbidities and quality of life in epilepsy","author":"Kutlu","year":"2016"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108358_b0205","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/epi.14008","article-title":"Development and assessment of the Quality of Life in Childhood epilepsy Questionnaire (QOLCE-16)","volume":"59","author":"Goodwin","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108358_b0215","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108358_b0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2165\/11208340-000000000-00000","article-title":"Spotlight on levetiracetam in epilepsy","volume":"25","author":"Lyseng-Williamson","year":"2011","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108358_b0225","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.janxdis.2010.07.001","article-title":"Psychometric properties of the Spence Child Anxiety Scale with adolescents from five European countries","volume":"25","author":"Essau","year":"2011","journal-title":"J Anxiety Disord"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108358_b0235","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40263-015-0281-8","article-title":"Antiepileptic drug treatment in children with epilepsy","volume":"29","author":"Rosati","year":"2015","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1535-7511.2007.00165.x","article-title":"New roles for interleukin-1 beta in the mechanisms of epilepsy","volume":"7","author":"Vezzani","year":"2007","journal-title":"Epilepsy Curr"},{"issue":"S2","key":"10.1016\/j.yebeh.2021.108358_b0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/epi4.12242","article-title":"Pharmacological targeting of brain inflammation in epilepsy: Therapeutic perspectives from experimental and clinical studies","volume":"3","author":"Ravizza","year":"2018","journal-title":"Epilepsia Open"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108358_b0250","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.seizure.2014.04.011","article-title":"Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans","volume":"23","author":"Guenther","year":"2014","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0255","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bbi.2008.03.009","article-title":"The role of cytokines in the pathophysiology of epilepsy","volume":"22","author":"Vezzani","year":"2008","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.yebeh.2021.108358_b0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2015.01.009","article-title":"IL-1\u03b2, IL-6 and IL1Ra levels in temporal lobe epilepsy","volume":"26","author":"Uludag","year":"2015","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108358_b0265","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00381-017-3359-4","article-title":"Cerebrospinal fluid neuron specific enolase, interleukin-1\u03b2 and erythropoietin concentrations in children after seizures","volume":"33","author":"Shi","year":"2017","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108358_b0270","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.pharep.2014.06.005","article-title":"Concentration of IL-1\u03b2, IL-2, IL-6, TNF\u03b1 in the blood serum in children with generalized epilepsy treated by valproate","volume":"66","author":"Steinborn","year":"2014","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.yebeh.2021.108358_b0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eplepsyres.2018.09.015","article-title":"The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy","volume":"148","author":"Gulcebi","year":"2018","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108358_b0280","first-page":"321","article-title":"Add-on levetiracetam in children and adolescents with refractory epilepsy: Results of an open-label multi-centre study","volume":"12","author":"Callenbach","year":"2008","journal-title":"Eur J Panti-seizure Medicationiatr Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0285","first-page":"077","article-title":"Efficacy of levetiracetam as first add-on therapy to carbamazepine and valproate sodium for children with epilepsy","volume":"03","author":"Kanemura","year":"2014","journal-title":"J Pediatr Epilepsy"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108358_b0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2018.01.018","article-title":"Safety of antiepileptic drugs in children and young people: a prospective cohort study","volume":"56","author":"Egunsola","year":"2018","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108358_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149686","article-title":"Safety of levetiracetam in panti-seizure medicationiatrics: a systematic review","volume":"11","author":"Egunsola","year":"2016","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.yebeh.2021.108358_b0305","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108358_b0310","first-page":"169","article-title":"Valproic acid for the treatment of social anxiety disorder","volume":"18","author":"Kinrys","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2021.108358_b0315","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2017.10.032","article-title":"Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study","volume":"79","author":"Rocamora","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108358_b0320","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.seizure.2006.11.009","article-title":"Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting","volume":"16","author":"Allain","year":"2007","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108358_b0325","doi-asserted-by":"crossref","first-page":"669","DOI":"10.18203\/2319-2003.ijbcp20181168","article-title":"Evaluation of levetiracetam and valproic acid as monotherapy on quality of life in patients of generalized tonic clonic epilepsy","volume":"7","author":"Verma","year":"2018","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108358_b0330","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2010.09.014","article-title":"A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy","volume":"20","author":"Yu","year":"2011","journal-title":"Seizure"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021006193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021006193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:44:03Z","timestamp":1761504243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021006193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":66,"alternative-id":["S1525505021006193"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108358","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108358"}}